Wandercraft stated that the FDA has approved expanded therapeutic indications for the Atalante X device, allowing its use for individuals with spinal cord injuries from levels C4 to L5, as well as for patients with multiple sclerosis. The earlier clearance applied only to individuals with SCI from levels T5 to L5 and stroke (CVA) patients. The device is now in use at over 100 rehabilitation and research centers worldwide, where it enables patients to collectively take more than one million steps per month.
What makes Atalante X stand out is its hands-free walking design — patients do not need to rely on crutches or walkers thanks to its self-balancing technology and powered hip, knee, and ankle joints. According to Wandercraft, the new version also allows precise joint configuration and step length adjustment in 5% increments, enabling therapists to tailor each session for patients with limited trunk or upper limb control.
The company emphasizes that this development represents a major advance in neurological rehabilitation, broadening access to cutting-edge mobility therapies for individuals previously considered unsuitable for such procedures. Wandercraft CEO Matthieu Masselin highlighted the company’s mission: “to help even those with severely limited upper body or trunk strength experience upright movement with confidence and safety.”
The expanded FDA clearance not only increases the potential user base but also opens the door for further technological progress. Wandercraft plans to continue the commercial rollout of Atalante X and develop a consumer version for home use.
It’s remarkable that a device often referred to as an “exoskeleton” can now genuinely help people with severe mobility impairments walk again. In the future, as such technologies become more widespread, exoskeletons may well become accessible to everyday users at home, beyond hospitals and rehabilitation centers.